Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

POSITIVE PROFIT ALERT

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that based on a preliminary review of the Group's unaudited consolidated management accounts for the six months ended June 30, 2025 (the "**Reporting Period**") in accordance with International Financial Reporting Standards, the expected results are as follow:

1) the revenue for the Reporting Period will exceed RMB480.0 million, representing a year-on-year increase of approximately 31.1% as compared to RMB366.0 million for the six months ended June 30, 2024. This substantial growth is primarily driven by sales of several key products, including the Kylin Flow Diverter, Neurovascular Guidewire, UltraFree Drug Coated PTA Balloon Catheter (UltraFree DCB), Octoplus Vena Cava Filter, and Phoenix Peripheral Detachable Fibrous Coil Embolization System.

2) the net profit attributable to the Company's equity holders for the Reporting Period will surpass RMB115.0 million, marking a year-on-year increase of approximately 66.9% as compared to RMB68.9 million for the six months ended June 30, 2024. This profit growth is primarily driven by increased revenue generated by targeted sales efforts, a stable gross profit margin resulting from high product quality and enhanced operational efficiency, and the implementation of a highly effective sales and marketing strategy.

As the Group's unaudited consolidated financial results for the Reporting Period have not yet been finalized, the information contained in this announcement is based on information that is currently available to the Board and the preliminary unaudited consolidated management accounts of the Group for the Reporting Period which have not yet been reviewed by the Company's auditors or audit committee. The actual financial results of the Group for the Reporting Period, which may be subject to adjustment(s) and which may differ from the information contained in this announcement, are expected to be published before the end of August 2025.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, July 23, 2025

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.